Embryonic vascular endothelial cells are malleable to reprogramming via Prox1 to a lymphatic gene signature
- 6k Downloads
In vivo studies demonstrate that the Prox1 transcription factor plays a critical role in the development of the early lymphatic system. Upon Prox1 expression, early lymphatic endothelial cells differentiate from the cardinal vein and begin to express lymphatic markers such as VEGFR-3, LYVE-1 and Podoplanin. Subsequent in vitro studies have found that differentiated vascular endothelial cells can be reprogrammed by Prox1 to express a lymphatic gene profile, suggesting that Prox1 can initiate the expression of a unique gene signature during lymphangiogenesis. While the in vitro data suggest that gene reprogramming occurs upon Prox1 expression, it is not clear if this is a direct result of Prox1 in vascular endothelial cells in vivo.
Overexpression of Prox1 in vascular endothelial cells during embryonic development results in the reprogramming of genes to that of a more lymphatic signature. Consequent to this overexpression, embryos suffer from gross edema that results in embryonic lethality at E13.5. Furthermore, hemorrhaging and anemia is apparent along with clear defects in lymph sac development. Alterations in junctional proteins resulting in an increase in vascular permeability upon Prox1 overexpression may contribute to the complications found during embryonic development.
We present a novel mouse model that addresses the importance of Prox1 in early embryonic lymphangiogenesis. It is clear that there needs to be a measured pattern of expression of Prox1 during embryonic development. Furthermore, Prox1 reprograms vascular endothelial cells in vivo by creating a molecular signature to that of a lymphatic endothelial cell.
KeywordsVascular Endothelial Cell Lymphatic Endothelial Cell Permeability Assay Cardinal Vein Podoplanin Expression
The specialization of the vasculature is driven by a number of molecular pathways that dictate the fate of blood vessels to that of an artery or vein . Following this initial programming, the development of the lymphatic system is dependent on the further differentiation of the venous endothelium. The newly differentiated lymphatic endothelial cells migrate in a polarized fashion to coalesce into an early lymph sac, which then progress to form the lymphatic vasculature proper [2, 3].
A number of genes have been found to be associated with the lymphatic endothelial cell profile, for example LYVE-1, Podoplanin and VEGFR-3 [4, 5, 6]. In addition to this profile, the transcription factor Prox1 has been found to act as an important regulatory switch, altering the molecular identity of venous endothelium and imparting them with attributes that augment lymphatic development. Indeed, genetic ablation of prox1 results in embryonic lethality; hemizygous null mice are found to die shortly after birth . In both cases, a major developmental defect was found to involve the emerging lymphatic system. Specifically, the early lymphatic endothelial cells (LECs) that normally bud off from the cardinal vein (CV) in a polarized manner do not do so. Instead, prox1 null LECs do not migrate, resulting in defective lymph sac formation and consequently no development of a functional lymphatic system. Furthermore, these null cells molecularly default to a more vascular-like phenotype. To this end, prox1 null mice display lymphedema and chylous ascites buildup resulting in death [2, 3].
It is clear that vascular endothelial cells require the regulated expression of Prox1 early in development, initiating a transcriptional program that results in lymphatic differentiation. This point underscores the plasticity of differentiated endothelial cells under the influence of Prox1. Indeed, microarray analysis of vascular endothelial cells engineered to overexpress Prox1 resulted in the upregulation of lymphatic specific genes while downregulating a number of blood specific genes [7, 8]; this study extending the known surface markers of lymphatic endothelial cells by providing a more in-depth characterization of LEC gene signature. The in vivo knockout data demonstrates that prox1 plays an important role in early lymphatic development. Furthermore, targeted deletion of prox1 within vascular endothelial cells recapitulates the lymphatic defect and the edematous phenotype . Moreover, in vitro studies suggest that this lymphatic defect is potentially due to an inability to molecularly reprogram early vascular endothelial cells to a lymphatic fate [7, 8]. Given this however, it is not clear whether the reprogramming to a specific gene signature does indeed occur in vivo. Here we describe an in vivo model to address the molecular significance of Prox1 in reprogramming vascular endothelial cells to that of a lymphatic gene profile.
Prox1 expression in double transgenic mice
Phenotype of DT Prox1 mice
Analysis of number of embryos and postnatal births.
DT expected 25%
Ratio of observed:absent**(%) 76:24
DT observed 14.6%
DT expected 25%
Ratio of observed:absent (%) 58:42
DT observed 10.9%
DT expected 25%
Ratio of observed:absent (%) 44:56
DT observed 16.7%
DT expected 25%
Ratio of observed:absent (%) 67:33
Marker analysis of yolk sacs from Prox1 DT mice
Jugular veins from Prox1 DT embryos display lymphatic markers
Overexpression of Prox1 correlates with changes in junctional proteins in vivo and in vitro
The importance of Prox1 in initializing differentiation was shown to be a result of its ability to reprogram blood endothelial cells to a lymphatic endothelial cell profile. This molecular switch shown in vitro suggested that Prox1 initiates the transcriptional machinery necessary for lymphangiogenesis [8, 11]. While the Prox1 knockout study as well as a tissue specific deletion of Prox1 in the endothelium  point to the necessity of Prox1 in lymphatic development, it does not provide a complete extension on the molecular players that confer the ability to reprogram the blood vasculature as suggested from in vitro studies [7, 8]. To this end, one way to address this involves the specific overexpression of Prox1 in the endothelial cell compartment. In the present study, we examine the importance of vascular reprogramming and fate specificity in vivo with a tie1/prox1 bigenic mouse model that specifically expresses Prox1 in early vascular endothelial cells.
Early expression of Prox1 in vascular endothelial cells result in no overt embryonic phenotype, however as development progresses Prox1 double transgenic embryos appear growth delayed and display more overt bleeding. Of the most serious cases, DT embryos are anemic and edematous. This correlated with the alteration of a number of molecular targets associated with vascular reprogramming such as an increase in VEGFR-3, Neuropilin-2 and STAT6 and a decrease in Neuropilin-1, VEGFR-2, Tie-2 and CyclinE2 [7, 8, 12]. Examination of the most severely affected DT embryos show a general degradation of the embryonic structure, separation of the epidermis and enlarged lymph sacs when compared to their wild type counterparts. Furthermore, vascular structures such as the jugular vein, which normally express low levels of VEGFR-3 and Podoplanin are now highly positive for these lymphatic markers. In conjunction with previous data demonstrating the importance of Prox1 in BEC differentiation to LECs, we present data that provides further in vivo evidence of the molecular players involved in the reprogramming of BECs to LECs early in lymphatic vascular development. Consistent with our data, it was recently observed that Sox18 is upstream of Prox1; in vitro overexpression of Sox18 in embryonic stem cells and vascular endothelial cells results in the upregulation of Prox1 and an increase in lymphatic markers such as Podoplanin, indirectly confirming our data presented here . In addition, the conditional deletion of Prox1 results in the dedifferentiation of lymphatic endothelial cells to that of a more vascular endothelial cell-like phenotype . This further suggests that Prox1 is critical for the maintenance of the lymphatic endothelial cell fate, and that endothelial cells are genetically malleable. Our in vivo study further confirms the importance of Prox1 in generating a lymphatic profile by altering the gene signature of vascular endothelial cells.
One consequence that results from the overexpression of Prox1 in the vascular compartment of the developing embryo is edema. At the histological level, we observe the separation of the dermal layer from the epidermis as a result of fluid leakage, characteristic of an improper lymphatic drainage system. Furthermore, a prominent feature of the most severely affected embryos is the enlargement of the lymph sacs. It is unclear as to the mechanism of the increased size, whether it is from an increase in the number of differentiating early lymphatic endothelial cells budding from the jugular vein, or from an increase in proliferation of committed lymphatic endothelial cells that are in the process of or have already formed the lymph sac. Interestingly, early analysis of E10.5 DT embryos show an increase in Prox1 positive cells in the periphery; this increase in population may play a contributing factor to the increase in lymph sac size. The potential for an increase in proliferation due to Prox1 overexpression is consistent with previously published work that identifies the upregulation of a number of cell cycle targets such as CyclinE2 and p57kip .
The data suggests that the overexpression of Prox1 during early embryogenesis results in the reprogramming of vascular endothelial cells to a more lymphatic cell fate resulting in edema, hemorrhaging and death. While it demonstrates the importance of tightly regulating Prox1 in development, it is unclear as to why the hemorrhaging occurs. In our model, one can hypothesize that the overexpression of Prox1 may influence junctional proteins involved in maintaining the integrity of cell-cell contacts; alterations in these same complexes may result in changes in vascular permeability leading to a more permeable, lymphatic-like state . Indeed, upon Prox1 overepression changes in junctional proteins are observed away from the normal molecular profile associated with control embryos. Previous studies have shown that increases as well as decreases in junction protein levels have been shown to be associated with an increase in permeability [16, 17], suggesting that a balance is required in order to maintain the integrity of the cell-cell interface. Recent data has found that the overexpression of Prox1 in colon epithelial cells result in dysplasia and transformation that correlates with changes in cellular adhesion . Furthermore, conditional deletion of Prox1 results in aberrant junctional complex formation and abnormal pericyte association . These lines of evidence point to the importance of cell-cell integrity in the regulation of vascular permeability. Moreover, the controlled expression of Prox1 is critical for normal lymphatic development in the embryo.
It is clear that the measured expression of Prox1 as well as other lymphangiogenic factors during embryonic development is essential for the proper formation of the lymphatic vasculature. Not surprisingly, compromising this regulated expression has been found to result in negative clinical consequences. For example, the growth of lymphatic endothelium in tumors is a result of the presence of VEGF-C, which acts on lymph vessels to enhance metastasis . Other events include the transformation and cellular reprogramming of spindle-like lesional cells by Karposi sarcoma herpesvirus (KHSV)/human herpesvirus-8 (HHV8). Interestingly, gene profiling of KHSV infected lesional cells produce a signature similar to that derived from a lymphatic endothelial cell; targets that include Prox1, LYVE-1 and VEGFR-3. This suggests that Karposi sarcoma genetically mimics an expression pattern similar to a differentiated lymphatic endothelial cell [19, 20, 21].
In conclusion, we extend the previous in vitro studies that characterized the molecular profile of reprogrammed vascular endothelial cells that overexpress the Prox1 transcription factor. Furthermore, we also demonstrate that the tight regulation of Prox1 is critical for normal embryonic lymphatic development. While the expression pattern of Prox1 in our model does not fully recapitulate the GFP expression found in the Tie1-GFP mouse model, it is clear that when Prox1 is overexpressed in our tissue specific model it results in aberrant lymph sac development, hemorrhaging, edema, anemia and ultimately, embryonic lethality. In a corresponding study, Johnson et al. demonstrated that Prox1 was essential for the maintenance of the lymphatic phenotype, where a global temporal deletion of Prox1 during mid-development effectively deprograms lymphatic structures to that of a vascular endothelial-like phenotype, assessed by surface markers such as Podoplanin and SLC . Our data presented here complement the work by Johnston et al., whereby the tissue specific overexpression of Prox1 reprograms similar markers to a more lymphatic-like profile. Furthermore, we elucidate some of the molecular components that accompany vascular endothelial cell reprogramming involved in early lymphatic differentiation and development. The development of our unique model complements and extends the current viewpoint of Prox1 being an important initiator of lymphatic development via its ability to reprogram endothelial cells to a specific molecular profile.
Generation of mice
The Animal Care and Ethics Committee approved all animals and protocols that were used. The construction of the tie1 and tie2 tTA driver transgene has been previously described . The prox1 cDNA was inserted into the pTet OS responder construct and transgenic animals were derived at the McGill Transgenic Facility, Montreal, Quebec, Canada. Driver and responder transgenic animals were bred to generate bigenic embryos. Embryos were genotyped and wild type, single and double transgenics in the presence of doxycycline was used as controls relative to double transgenics without doxycycline. Doxycycline treatment involved the addition of 100 μg/mL of doxycycline/5% sucrose in the drinking water and changed at least twice per week.
Immunofluorescence and immunohistochemistry
Embryos were prepared by fixing in 4% paraformaldyhyde, followed by incubation in 30% sucrose and mounted in OCT for cryosectioning. Sections were treated with 0.5% TritonX-100/PBS and blocked in 5%BSA/10%goat serum prior to antibody incubation. Antibodies used were anti-Prox1 (102PA30, RDI), Podoplanin (clone 8.1.1) and VEGFR-3 (16-5988, eBiosciences). Immunohistochemistry was counterstained with Harris hematoxylin.
Yolk sacs were placed in Trizol (GibcoBRL) and processed following manufacturers protocol. In brief, tissues were homogenized and 200 μL of chloroform was added per 1 mL Trizol. Following centrifugation at 10,000 × g for 15 minutes at 4°C, the upper phase was removed and 300 μL of 100% ethanol was added per 1 mL of Trizol. After 5 minutes incubation at room temperature, RNA was isolated by centrifugation at 2,000 × g for 5 minutes at 4°C. Proteins were then precipitated from the phenol-ethanol supernatant by 1.5 mL isopropyl alcohol per 1 mL Trizol. After 10 minutes incubation at room temperature, protein precipitate was isolated at 12,000 × g for 10 minutes at 4°C. Reverse transcriptase was performed as per manufacturers protocol (Qiagen). Negative control represents no template. PCR primers used were as follows:
mVEGFR-2 For: ATGAAATTGAGCTATCTGCC, Rev: CCACTGGATGTGGTGCAGGG
mNeuropilin-1For: GCAATAGCAAAAGAAGGTTT, Rev: ACCATGCCCAACAATCCAGA
mStat6 For: ATCCAGCTTCAGGCCCTGTC, Rev: TCTATCTGTGAGGAGCCATC
mCyclinE2 For: ATCCAGTCTACAGATTCCGA, Rev: ATCCAGTCTACAGATTCCGA
Prox1 For: ATGCCTGACCATGACAGC, Rev: GGGAAGCTTTTGCTTGCG
mJAM-1 For: CCGAGTGGAGTGGAAGTTCGTCC, Rev: AGGAACGACGAGGTCTGTTTGAATTC
mOccludin For: ACTTCAGGCAGCCTCGGTACAG, Rev: CTCCCGCAACTGGCATCTCTCTAA
mZO-1For: TCACAGGGCTCCTGGGTTTGGAT, Rev: CTAGTGACTGAATTTCTGAAATGTCATCT
GAPDH For: CTGCACCACCAACTGCTTAG, Rev: TCTCATCATACTTGGCAGGT
Venous endothelial cells used in this study have been previously characterized . Proteins were lysed in RIPA buffer for 30 minutes on ice (10 mM NaH2PO4 pH7.5, 150 mM NaCl, 1% NP-40, 0.1% SDS, 1% Sodium Deoxycholate, 10 mM NaF, 2 mM EDTA, Protease Inhibitor cocktail (Complete-EDTA free, Roche USA), and 10 mM sodium orthovanadate, cleared by centrifugation and the supernatants collected for further analysis. Equal amounts of lysates were resuspended with 2xSDS loading buffer and separated via SDS-PAGE. Proteins were transferred to PVDF, blocked with 3% milk/tris buffered saline, incubated with the appropriate primary and secondary antibody conjugated to horse radish peroxidase, and developed via enhanced chemiluminescence (Pierce). Antibodies used include Prox-1 (07-537, Upstate), CD31 (557355, BD Biosciences), ZO-1 (40-2300, Zymed) and β-actin (AC15, Sigma).
This protocol is a modification of the permeability assay by Chemicon (ECM640). To generate Prox1 overexpressing cells, bovine VECs  were transfected with a human Prox1 cDNA via Lipofectamine 2000 as per manufacturers protocol (Gibco). 2 × 105 cells were plated in a 3 μm pore size transwell with no substrate. Positive controls included 100 ng/mL of VEGF-A/25 mM EDTA in the top well. Also included in the top well was 250 μg/mL of FITC-Albumin to quantitate permeability through the cell monolayer. After the cells were incubated for 48 hours, passage of FITC-Albumin (250 μg/mL) into the bottom chamber was detected at an excitation/emission ratio of 488/530. n = 3, performed in triplicate.
Data was presented as standard errors from the mean. Statistical significance was taken at P < 0.05 using an unpaired, two-tailed Student's t-test.
H.K. was supported by a postdoctoral fellowship from the Susan G. Komen Foundation (PDF0600259); V.P.K.H.N is supported by a Canadian Institutes of Health Research, Banting and Best Canadian Graduate Scholar Award; D.J.D. is the Canadian Research Chair for Angiogenic and Lymphangiogenic Signaling; Funding was provided by the Heart and Stroke Foundation of Canada (T-6123). Many thanks to Drs. Paul Van Slyke, Annie Bourdeau and Jennifer Alami for critical reading and helpful input.
- 5.Schacht V, Ramirez MI, Hong YK, Hirakawa S, Feng D, Harvey N, Williams M, Dvorak AM, Dvorak HF, Oliver G, et al: T1alpha/podoplanin deficiency disrupts normal lymphatic vasculature formation and causes lymphedema. Embo J. 2003, 22: 3546-56. 10.1093/emboj/cdg342.PubMedCentralCrossRefPubMedGoogle Scholar
- 6.Kaipainen A, Korhonen J, Mustonen T, van Hinsbergh VW, Fang GH, Dumont D, Breitman M, Alitalo K: Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. Proc Natl Acad Sci USA. 1995, 92: 3566-70. 10.1073/pnas.92.8.3566.PubMedCentralCrossRefPubMedGoogle Scholar
- 7.Petrova TV, Makinen T, Makela TP, Saarela J, Virtanen I, Ferrell RE, Finegold DN, Kerjaschki D, Yla-Herttuala S, Alitalo K: Lymphatic endothelial reprogramming of vascular endothelial cells by the Prox-1 homeobox transcription factor. Embo J. 2002, 21: 4593-9. 10.1093/emboj/cdf470.PubMedCentralCrossRefPubMedGoogle Scholar
- 11.Petrova TV, Nykanen A, Norrmen C, Ivanov KI, Andersson LC, Haglund C, Puolakkainen P, Wempe F, von Melchner H, Gradwohl G, et al: Transcription factor PROX1 induces colon cancer progression by promoting the transition from benign to highly dysplastic phenotype. Cancer Cell. 2008, 13: 407-19. 10.1016/j.ccr.2008.02.020.CrossRefPubMedGoogle Scholar
- 12.Y Xu, Yuan L, Mak J, Pardanaud L, Caunt M, Kasman I, Larrivee B, Del Toro R, Suchting S, Medvinsky A, et al: Neuropilin-2 mediates VEGF-C-induced lymphatic sprouting together with VEGFR3. J Cell Biol. 188: 115-30.Google Scholar
- 19.Jussila L, Valtola R, Partanen TA, Salven P, Heikkila P, Matikainen MT, Renkonen R, Kaipainen A, Detmar M, Tschachler E, et al: Lymphatic endothelium and Kaposi's sarcoma spindle cells detected by antibodies against the vascular endothelial growth factor receptor-3. Cancer Res. 1998, 58: 1599-604.PubMedGoogle Scholar
- 20.Wang HW, Trotter MW, Lagos D, Bourboulia D, Henderson S, Makinen T, Elliman S, Flanagan AM, Alitalo K, Boshoff C: Kaposi sarcoma herpesvirus-induced cellular reprogramming contributes to the lymphatic endothelial gene expression in Kaposi sarcoma. Nat Genet. 2004, 36: 687-93. 10.1038/ng1384.CrossRefPubMedGoogle Scholar
- 21.Weninger W, Partanen TA, Breiteneder-Geleff S, Mayer C, Kowalski H, Mildner M, Pammer J, Sturzl M, Kerjaschki D, Alitalo K, et al: Expression of vascular endothelial growth factor receptor-3 and podoplanin suggests a lymphatic endothelial cell origin of Kaposi's sarcoma tumor cells. Lab Invest. 1999, 79: 243-51.PubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.